CROSS COUNTRY HEALTHCARE INC (CCRN) Stock Fundamental Analysis
USA - NASDAQ:CCRN - US2274831047 - Common Stock
13.33 USD
+0.45 (+3.49%)
We assign a fundamental rating of 5 out of 10 to CCRN. CCRN was compared to 101 industry peers in the Health Care Providers & Services industry. While CCRN has a great health rating, its profitability is only average at the moment. CCRN does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
CCRN had positive earnings in the past year.
In the past year CCRN had a positive cash flow from operations.
In multiple years CCRN reported negative net income over the last 5 years.
CCRN had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -1.51%, CCRN is in line with its industry, outperforming 42.57% of the companies in the same industry.
CCRN has a Return On Equity (-2.02%) which is comparable to the rest of the industry.
Looking at the Return On Invested Capital, with a value of 1.44%, CCRN is in line with its industry, outperforming 43.56% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for CCRN is significantly above the industry average of 9.19%.
The last Return On Invested Capital (1.44%) for CCRN is well below the 3 year average (15.05%), which needs to be investigated, but indicates that CCRN had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.51% | ||
| ROE | -2.02% | ||
| ROIC | 1.44% |
ROA(3y)9.37%
ROA(5y)8.5%
ROE(3y)17.7%
ROE(5y)17.81%
ROIC(3y)15.05%
ROIC(5y)13.58%
1.3 Margins
CCRN has a Operating Margin (0.78%) which is comparable to the rest of the industry.
CCRN's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 20.19%, CCRN perfoms like the industry average, outperforming 42.57% of the companies in the same industry.
CCRN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.78% | ||
| PM (TTM) | N/A | ||
| GM | 20.19% |
OM growth 3Y-77.97%
OM growth 5Y-33.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.01%
GM growth 5Y-3.83%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CCRN is still creating some value.
Compared to 1 year ago, CCRN has less shares outstanding
Compared to 5 years ago, CCRN has less shares outstanding
CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.99 indicates that CCRN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.99, CCRN belongs to the top of the industry, outperforming 84.16% of the companies in the same industry.
CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.99 |
ROIC/WACC0.17
WACC8.69%
2.3 Liquidity
CCRN has a Current Ratio of 3.21. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 3.21, CCRN belongs to the best of the industry, outperforming 85.15% of the companies in the same industry.
CCRN has a Quick Ratio of 3.21. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CCRN (3.21) is better than 86.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.21 | ||
| Quick Ratio | 3.21 |
3. Growth
3.1 Past
CCRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -78.35%.
CCRN shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 24.57% yearly.
Looking at the last year, CCRN shows a very negative growth in Revenue. The Revenue has decreased by -24.30% in the last year.
Measured over the past years, CCRN shows a quite strong growth in Revenue. The Revenue has been growing by 10.33% on average per year.
EPS 1Y (TTM)-78.35%
EPS 3Y-47.22%
EPS 5Y24.57%
EPS Q2Q%-110%
Revenue 1Y (TTM)-24.3%
Revenue growth 3Y-7.11%
Revenue growth 5Y10.33%
Sales Q2Q%-19.34%
3.2 Future
The Earnings Per Share is expected to decrease by -16.16% on average over the next years. This is quite bad
CCRN is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.63% yearly.
EPS Next Y-68.27%
EPS Next 2Y-21.05%
EPS Next 3Y-16.16%
EPS Next 5YN/A
Revenue Next Year-16.68%
Revenue Next 2Y-8.76%
Revenue Next 3Y-5.63%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 63.48, CCRN can be considered very expensive at the moment.
The rest of the industry has a similar Price/Earnings ratio as CCRN.
Compared to an average S&P500 Price/Earnings ratio of 27.20, CCRN is valued quite expensively.
CCRN is valuated quite expensively with a Price/Forward Earnings ratio of 47.52.
CCRN's Price/Forward Earnings ratio is in line with the industry average.
CCRN is valuated expensively when we compare the Price/Forward Earnings ratio to 22.71, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 63.48 | ||
| Fwd PE | 47.52 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CCRN is valued a bit cheaper than 61.39% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CCRN is valued cheaply inside the industry as 83.17% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.81 | ||
| EV/EBITDA | 12.59 |
4.3 Compensation for Growth
CCRN's earnings are expected to decrease with -16.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)2.58
EPS Next 2Y-21.05%
EPS Next 3Y-16.16%
5. Dividend
5.1 Amount
CCRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CCRN (9/17/2025, 12:43:45 PM)
13.33
+0.45 (+3.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners100.48%
Inst Owner Change-1.99%
Ins Owners5.37%
Ins Owner Change-0.22%
Market Cap436.69M
Analysts52.31
Price Target18.44 (38.33%)
Short Float %7.3%
Short Ratio7.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-56.4%
Min EPS beat(2)-118.38%
Max EPS beat(2)5.59%
EPS beat(4)2
Avg EPS beat(4)-39.17%
Min EPS beat(4)-118.38%
Max EPS beat(4)22.23%
EPS beat(8)4
Avg EPS beat(8)-22%
EPS beat(12)8
Avg EPS beat(12)-10.41%
EPS beat(16)12
Avg EPS beat(16)-0.77%
Revenue beat(2)0
Avg Revenue beat(2)-6.65%
Min Revenue beat(2)-7.46%
Max Revenue beat(2)-5.84%
Revenue beat(4)0
Avg Revenue beat(4)-3.61%
Min Revenue beat(4)-7.46%
Max Revenue beat(4)-0.41%
Revenue beat(8)1
Avg Revenue beat(8)-2.19%
Revenue beat(12)4
Avg Revenue beat(12)-0.89%
Revenue beat(16)7
Avg Revenue beat(16)0.6%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-42.1%
EPS NQ rev (3m)-54.16%
EPS NY rev (1m)-54.2%
EPS NY rev (3m)-61.11%
Revenue NQ rev (1m)-3.06%
Revenue NQ rev (3m)-8.37%
Revenue NY rev (1m)-5.08%
Revenue NY rev (3m)-7.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 63.48 | ||
| Fwd PE | 47.52 | ||
| P/S | 0.37 | ||
| P/FCF | 12.81 | ||
| P/OCF | 10.5 | ||
| P/B | 1.06 | ||
| P/tB | 1.82 | ||
| EV/EBITDA | 12.59 |
EPS(TTM)0.21
EY1.58%
EPS(NY)0.28
Fwd EY2.1%
FCF(TTM)1.04
FCFY7.81%
OCF(TTM)1.27
OCFY9.53%
SpS36.4
BVpS12.58
TBVpS7.31
PEG (NY)N/A
PEG (5Y)2.58
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.51% | ||
| ROE | -2.02% | ||
| ROCE | 2.04% | ||
| ROIC | 1.44% | ||
| ROICexc | 1.75% | ||
| ROICexgc | 3.24% | ||
| OM | 0.78% | ||
| PM (TTM) | N/A | ||
| GM | 20.19% | ||
| FCFM | 2.86% |
ROA(3y)9.37%
ROA(5y)8.5%
ROE(3y)17.7%
ROE(5y)17.81%
ROIC(3y)15.05%
ROIC(5y)13.58%
ROICexc(3y)15.28%
ROICexc(5y)13.73%
ROICexgc(3y)22.9%
ROICexgc(5y)20.79%
ROCE(3y)21.31%
ROCE(5y)19.23%
ROICexcg growth 3Y-75.41%
ROICexcg growth 5Y-32.32%
ROICexc growth 3Y-77.25%
ROICexc growth 5Y-30.83%
OM growth 3Y-77.97%
OM growth 5Y-33.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.01%
GM growth 5Y-3.83%
F-Score5
Asset Turnover2.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 42.39% | ||
| Cap/Sales | 0.63% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 153.74% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.21 | ||
| Quick Ratio | 3.21 | ||
| Altman-Z | 4.99 |
F-Score5
WACC8.69%
ROIC/WACC0.17
Cap/Depr(3y)64.63%
Cap/Depr(5y)60.57%
Cap/Sales(3y)0.55%
Cap/Sales(5y)0.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-78.35%
EPS 3Y-47.22%
EPS 5Y24.57%
EPS Q2Q%-110%
EPS Next Y-68.27%
EPS Next 2Y-21.05%
EPS Next 3Y-16.16%
EPS Next 5YN/A
Revenue 1Y (TTM)-24.3%
Revenue growth 3Y-7.11%
Revenue growth 5Y10.33%
Sales Q2Q%-19.34%
Revenue Next Year-16.68%
Revenue Next 2Y-8.76%
Revenue Next 3Y-5.63%
Revenue Next 5YN/A
EBIT growth 1Y-69.02%
EBIT growth 3Y-79.54%
EBIT growth 5Y-27.01%
EBIT Next Year635.23%
EBIT Next 3Y126.18%
EBIT Next 5YN/A
FCF growth 1Y-88.57%
FCF growth 3YN/A
FCF growth 5Y112.02%
OCF growth 1Y-86.63%
OCF growth 3YN/A
OCF growth 5Y85.29%